Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Tacalyx, a Germany-based cancer therapeutics developer spun out of Max Planck Institute (MPI) of Colloids and Interfaces, today secured €7m ($7.7m) of seed funding from investors co-led by Kurma Partners and Boehringer Ingelheim Venture Fund, part of pharmaceutical firm Boehringer Ingelheim. Public-private partnership High-Tech Gründerfonds also contributed capital alongside Idinvest Partners, Coparion and Creathor Ventures. Tacalyx hopes to leverage antibodies against tumour-associated carbohydrate antigens that have been identified as a pathway to modulating the virulence of tumour cells. Its scientific…
